Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Glytec
AddedFeb 15, 2024
UpdatedJun 18, 2026
Glytec

Glytec

Series A

Glytec: Pioneering insulin management software for personalized, cost-effective diabetes care.

HQ
Greenville, SC, US
Founded
2006
Overview
Compare
Fundraising
Employees
Website

Founded with a mission to revolutionize diabetes care, Glytec offers advanced insulin management software designed for healthcare providers. The company’s core vision is to improve the quality and cost of diabetes treatment through personalized care. Glytec’s FDA-cleared titration software and proprietary algorithms provide tailored diabetes treatment recommendations, enhancing patient safety and outcomes. Their SaaS platform is widely adopted by hospitals, facilitating collaborative diabetes management and reducing workflow errors.

Glytec has garnered support from notable healthcare leaders and investors, contributing to its rapid growth and industry recognition. The company’s key achievements include significant reductions in patient length of stay and ICU bed usage, alongside an impressive 8x ROI for healthcare facilities. Glytec’s impact is evident in its widespread adoption across numerous hospitals, where it continues to set new standards in diabetes and insulin management.

Glytec - Similar Companies

Glycostasis logo

Glycostasis

Hygieia logo

Hygieia

hygieia.com

Databetes logo

Databetes

Monarch Medical Technologies logo

Monarch Medical Technologies

monarchmedtech.com

Glysens logo

Glysens

Pops! Diabetes Care logo

Pops! Diabetes Care

popsdiabetes.com

Diatech Diabetes logo

Diatech Diabetes

GlucoIQ logo

GlucoIQ

Insulet logo

Insulet

insulet.com

Glyscend logo

Glyscend

glyscend.com

One Drop logo

One Drop

onedrop.today

Better Living Technologies logo

Better Living Technologies

Tandem Diabetes Care logo

Tandem Diabetes Care

tandemdiabetes.com

Glooko logo

Glooko

glooko.com

Diabetes Care Group logo

Diabetes Care Group

Glytec - Quick Facts

Who are Glytec's competitors?

Companies similar to Glytec include Glycostasis, Hygieia, Databetes and Monarch Medical Technologies.

When was Glytec founded?

Glytec was founded in 2006.

Where is Glytec's headquarters located?

Glytec's headquarters is located in Greenville, SC, US.

When was Glytec's last funding round?

Glytec's most recent funding round was for $12M (USD) in April 2021.

How much has Glytec raised to-date?

As of Apr 26, 2021, Glytec has raised a total of $42M (USD).

How many employees does Glytec have?

Glytec has 115 employees as of Feb 4, 2024.

Glytec - Classification

Technology
  • AI
  • Analytics
Geographic Exposure
  • Americas
Model
  • Platform
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
  • Small Business
Main Product
  • Diabetes Care
  • Insulin Management
Tags
  • Healthtech
  • SaaS
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7372Prepackaged Software
Show 4 more industry codes
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified